Weill Cornell Medicine has received a four-year, $8.2 million grant from the National Institute of Child Health and Human Development (NICHD) to develop and test an experimental on-demand male contraceptive pill that temporarily stops sperm in their tracks.
Weill Cornell Graduate School of Medical Sciences celebrated students in the Class of 2025 for their academic achievements during its convocation ceremony on May 14.
An experimental contraceptive drug candidate developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models.
The sixth annual Symposium on Entrepreneurship and Academic Drug Development, hosted Nov. 14, showcased Weill Cornell’s rich array of programs for supporting faculty who want to bring their discoveries to the health care marketplace.
